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Abstract
Background: Our previous work found that serine/arginine-rich splicing factor 3 (SRSF3) was overexpressed in
human ovarian cancer and the overexpression of SRSF3 was required for ovarian cancer cell growth and survival.
The mechanism underlying the role of SRSF3 in ovarian cancer remains to be addressed.
Methods: We conducted microarray analysis to profile the gene expression and splicing in SRSF3-knockdown
cells and employed quantitative PCR and western blotting to validate the profiling results. We used chromatin
immunoprecipitation to study transcription and the direct repeat green fluorescent protein reporter assay to study
homologous recombination-mediated DNA repair (HRR).
Results: We identified 687 genes with altered expression and 807 genes with altered splicing in SRSF3-knockdown
cells. Among expression-altered genes, those involved in HRR, including BRCA1, BRIP1 and RAD51, were enriched
and were all downregulated. We demonstrated that the downregulation of BRCA1, BRIP1 and RAD51 expression
was caused by decreased transcription and not due to increased nonsense-mediated mRNA decay. Further, we
found that SRSF3 knockdown impaired HRR activity in the cell and increased the level of γ-H2AX, a biomarker for
double-strand DNA breaks. Finally, we observed that SRSF3 knockdown changed splicing pattern of KMT2C, a
H3K4-specific histone methyltransferase, and reduced the levels of mono- and trimethylated H3K4.
Conclusion: These results suggest that SRSF3 is a new regulator of HRR process, which possibly regulates the
expression of HRR-related genes indirectly through an epigenetic pathway. This new function of SRSF3 not only
explains why overexpression of SRSF3 is required for ovarian cancer cell growth and survival but also offers a new
insight into the mechanism of the neoplastic transformation.
Background
Serine/arginine-rich splicing factor 3 (SRSF3), previously
named as SRp20 and SFRS3, is the smallest member of
serine/arginine-rich (SR) protein family, well known for
its regulatory roles in RNA metabolism and functions,
such as pre-mRNA splicing [1–4], mRNA 3′ end pro-
cessing [5, 6], mRNA export from nucleus [7–9] and
cap-independent translation [10, 11]. SRSF3 was also
implicated in the regulation of chromatin structure and
function because of its association with interphase
chromatin but not with hyperphosphorylated mitotic
chromosomes [12].
Physiologically, SRSF3 is essential for embryo develop-
ment since Srsf3-null mouse embryos failed to form blasto-
cysts and died at the morula stage [13]. Mice with
hepatocyte-specific knockout of Srsf3 exhibited altered hep-
atic architecture, prolonged expression of fetal liver
markers, impaired glucose homeostasis and reduced chol-
esterol synthesis, suggesting that Srsf3 is indispensable for
hepatocyte maturation and metabolic function in mice [14].
Pathologically, there is increasing evidence indicating
that SRSF3 plays an important role in tumorigenesis. In
a mouse model of mammary tumorigenesis, it was ob-
served that SRSF3 was remarkably increased during the
development of mammary cancer [15]. In human ovar-
ian tumors, we found that SRSF3 was overexpressed in
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invasive ovarian cancer at all stages and its overexpres-
sion was critical for tumor cell growth and maintenance
of transformation properties [16, 17]. Knockdown of
SRSF3 expression causes growth inhibition or apoptosis
of ovarian cancer cells, depending on the extent of
SRSF3 knockdown [16]. SRSF3 was also found upregu-
lated in a variety of other tumors, such as cervical cancer
and rhabdomyosarcoma [18]. It was showed that ectop-
ically expressed SRSF3 promoted cell growth and trans-
formation of human and mouse fibroblasts [18]. In
addition, knockdown of SRSF3 resulted in G1 arrest
and downregulation of several G1/S transition-related
genes in colon cancer cells [19] and led to p53-
dependent cellular senescence in fibroblasts [20]. Be-
sides the tumor promoting role, a recent study found
that SRSF3 might function as a suppressor of hepatic
carcinogenesis, because mice with hepatocyte-specific
knockout of Srsf3 invariably developed hepatocellular
carcinoma at late ages [21].
Our previous studies mentioned above raise questions
why SRSF3 is required for ovarian cancer cell growth
and how it contributes to the neoplastic transformation.
In the present study, we show that knockdown of SRSF3
suppresses expression of breast cancer 1, early onset
(BRCA1), BRCA1 interacting protein C-terminal helicase
1 (BRIP1), and RAD51 recombinase (RAD51). These
genes all play important roles in the homologous recom-
bination (HR)-mediated DNA damage repair pathway
[22, 23]. Correspondingly, we observed impaired HR-
mediated DNA damage repair (HRR) activity and accu-
mulation of DNA double-strand breaks (DSBs) after
SRSF3 knockdown. We also provide evidence suggesting
that SRSF3 possibly regulates the expression of above
genes through an epigenetic pathway.
Results
Profiling of gene expression and splicing in SRSF3-
knockdown cells
In our previous study, we established three A2780
sublines, A2780/SRSF3si1, A2780/SRSF3si2 and A2780/
LUCsi, which express doxycycline (Doxy)-induced SRSF3
siRNA1 (SRSF3si1), SRSF3 siRNA2 (SRSF3si2) and lucif-
erase siRNA (LUCsi), respectively. SRSF3si1 and SRSF3si2
suppress SRSF3 expression by about 50 and 90 %,
respectively, while LUCsi has little effect on SRSF3 expres-
sion [16]. We confirmed these results in the present study
by regular reverse transcription PCR (RT-PCR), quantita-
tive RT-PCR (qPCR) as well as western blotting, as shown
in the Fig. 2a, b and c. Induction of SRSF3si1 caused cell
growth inhibition whereas induction of SRSF3si2 led to
apoptosis [16] (Fig. 2f). In order to determine the mecha-
nisms underlying the role of SRSF3 in ovarian cancer, we
conducted human exon microarray analysis to examine
the genome-wide profiles of gene expression and splicing
in A2780/SRSF3si2 cells with or without SRSF3 knock-
down. Using p < 0.05 and absolute fold changes greater
than 2 as the cutoff values, we found 687 genes altered in
their expression in SRSF3-knockdown cells, among which
424 genes were upregulated while 263 genes were down-
regulated (Additional file 1: Table S1). Using false discov-
ery rate (FDR) less than 0.05 as the criterion, we identified
807 genes altered in their splicing in the SRSF3si2 cells
(Additional file 2: Table S2). Shown in Fig. 1a is the Venn
diagram of expression-altered genes and splicing-altered
genes in SRSF3-knockdown cells. Gene ontology ana-
lysis revealed that genes involved in double-strand
break repair, especially those involved in HRR, were
enriched among the expression-altered genes, as
shown in Fig. 1b. Figure 1c lists the changed HRR-
related genes, which are all downregulated in SRSF3-
knockdown cells. In addition, genes involved in sterol
biosynthesis are also enriched in the expression-
altered genes and they are all upregulated in SRSF3-
knockdown cells (Additional file 3: Figure S1). Among
the splicing-altered genes, those involved in cellular
protein modification, especially those related to polyu-
biquitilation, are the most highly enriched (Additional
file 3: Figure S2).
Knockdown of SRSF3 suppresses the expression of
BRCA1, BRIP1 and RAD51
We have confirmed the downregulation of BRCA1,
BRIP1 and RAD51 expression induced by SRSF3 knock-
down at both mRNA and protein levels, as shown in
Fig. 2. We confirmed the downregulation of other three
genes, XRCC2, RAD54B and BLM, only at mRNA levels
(Additional file 3: Figure S3) but not at protein levels
due to problems with the antibodies we tested. Figure 2a
and b show the results of RT-PCR and qPCR, respect-
ively. Figure 2c shows the results of western blotting. As
can be seen, the downregulation of BRCA1, BRIP1 and
RAD51 is more substantial in Doxy-treated A2780/
SRSF3si2 cells than in Doxy-treated A2780/SRSF3si1
cells, indicating that the effects correlate with the extent
of SRSF3 knockdown. As the primer pairs used for PCR
are located on the exons common to all or most known
splice variants of these genes, the results shown in Fig. 2
reflect the downregulation of overall expression rather
than specific splice variants. Similar results were ob-
tained with sublines of another ovarian cancer cell line,
SKOV3, as shown in the Additional file 3: Figure S4, in-
dicating that the phenomenon is not cell line specific. It
is worth pointing out that our microarray analysis did
not find any significant alterations in the splicing of
BRCA1, BRIP1 and RAD51 in SRSF3-knockdown cells.
We also measured the time course of the expression
of BRCA1, BRIP1 and RAD51 at mRNA and protein
levels after the A2780/SRSF3si2 cells were treated with
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Doxy. As can be seen in Fig. 2d and e, the expression
of these genes started to decrease from day one after
Doxy treatment and the downregulation was gradually
intensified in the later days. These results suggest that
downregulation of these genes is likely a primary effect
of SRSF3 knockdown rather than secondary to the
growth inhibition or apoptosis caused by SRSF3 knock-
down, which was not observed until day 4 after Doxy
treatment, as shown in Fig. 2f.
SRSF3 knockdown-induced downregulation of BRCA1,
BRIP1 and RAD51 is not due to nonsense-mediated mRNA
decay (NMD)
NMD is an important quality-control mechanism but
also plays a role in the regulation of gene expression. It
recognizes and degrades mRNAs harboring premature
termination codons (PTCs) [24]. SRSF3 is a well-known
splicing factor and its knockdown may cause aberrant
splicing and thus trigger NMD to downregulate gene ex-
pression. To determine whether the downregulation of
BRCA1, BRIP1 and RAD51 is mediated by this mechan-
ism, we examined the effects of inhibition of NMD path-
way on the expression of these three genes. NMD is
primarily carried out by up-frameshift (UPF) proteins,
which consist of UPF1, UPF2 and UPF3 with UPF1 as
the key effector of NMD [25]. Previous studies showed
that depletion of UPF1 by shRNAs substantially inhib-
ited NMD activity, leading to the upregulation of hun-
dreds of mRNAs [26, 27]. We introduced one of the
reported UPF1 siRNA (UPFsi) sequences [28] or LUCsi
sequence [29] into A2780/SRSF3si2 cells using lentiviruses
and achieved Doxy-induced simultaneous knockdown of
SRSF3 and UPF1, as shown in Fig. 3a. Then we measured
the expression of BRCA1, BRIP1 and RAD51 in these cells
A
B C
Fig. 1 Knockdown of SRSF3 alters expression and splicing of hundreds of genes. a Venn diagram of expression-altered genes and splicing-altered
genes. b Bar chart of enrichment scores under the term of DNA repair generated by gene ontology analysis. c List of expression-altered
HRR-related genes





Fig. 2 (See legend on next page.)
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treated with or without Doxy for 3 days by qPCR. As can
be seen in Fig. 3b, these genes were similarly downregu-
lated in A2780 cells simultaneously expressing SRSF3si2
and UPF1si or SRSF3si2 and LUCsi, indicating that the
downregulation of these genes could not be reversed by
inhibition of NMD and thus was not mediated by NMD.
Knockdown of SRSF3 suppresses the transcription of
BRCA1, BRIP1 and RAD51
To determine whether the downregulation of BRCA1,
BRIP1 and RAD51 is caused by reduced transcription,
we examined RNA polymerase II (RNApII) occupancy
on these genes in A2780/SRSF3si2 cells treated with or
without Doxy using chromatin immunoprecipitation
(ChIP) technology. RNApII occupancy on chromatin
DNA has been shown to be reliable surrogate readout
for transcription rates [30, 31]. We analyzed RNApII oc-
cupancy in two regions for each gene: one is about 1 kb
downstream of transcription start site (TSS) and the
other is 10 kb to 14 kb downstream of TSS. Chromatin
DNAs precipitated by RNApII antibody or negative control
IgG (Neg IgG) were analyzed by regular PCR and qPCR.
As shown in Fig. 4 (results of ChIP in the region of 1 kb
downstream of TSS) and Additional file 3: Figure S5
(results of ChIP in the region of 10 to 14 kb downstream of
TSS), RNApII occupancy was decreased in BRCA1, BRIP1
and RAD51 genes, but not in the control gene, GAPDH,
after SRSF3 knockdown. Figure 4a shows the results of
regular PCR and the Fig. 4b shows the results of qPCR.
Knockdown of SRSF3 impairs HRR and increases DSBs
Given the role of BRCA1, BRIP1 and RAD51 in HR-
mediated repair of DSBs, the downregulation of their ex-
pression is very likely to impair this process and cause
accumulation of DSBs in the cells. To test this hypothesis,
we first examined the levels of γ-H2AX, a biomarker of
(See figure on previous page.)
Fig. 2 Knockdown of SRSF3 suppresses the expression of BRCA1, BRIP1 and RAD51. a Regular PCR amplification of cDNA fragments of BRCA1,
BRIP1, RAD51, SRSF3 and GAPDH. b Relative quantitation of BRCA1, BRIP1, RAD51 and SRSF3 expression determined by qPCR analysis. Shown are
the results of three independent experiments (mean ± s.d.). * indicates p < 0.01 for comparisons between samples treated with and without Doxy.
c Left: Western blotting results of whole cell lysates of A2780 subline cells treated with or without Doxy. Right: Quantitation of the western
blotting results. Results in (a), (b) and (c) were obtained from cells treated with or without Doxy for 3 days. d Time course of BRCA1, BRIP1,
RAD51 and SRSF3 expression at mRNA levels determined by qPCR. Day 0 represents cells that were not treated with Doxy. Two independent
experiments were performed and produced similar results. Shown are the results of one experiment (mean ± s.d. of triplicate PCR reactions).
e Time course of BRCA1, BRIP1, RAD51 and SRSF3 expression at protein levels. Left: Western blotting results; Right: Quantitation. f Time
course of apoptotic cells
B
A
Fig. 3 SRSF3 knockdown-induced downregulation of BRCA1, BRIP1 and RAD51 is not due to NMD. a Western blotting results showing Doxy-induced
simultaneous knockdown of UPF1 and SRSF3. b Expression of BRCA1, BRIP1 and RAD51 after simultaneous knockdown of UPF1 and SRSF3. Shown are
the results of three independent experiments (mean ± s.d)
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DSBs, in A2780 subline cells treated with or without Doxy
by western blotting. As shown in Fig. 5a, γ-H2AX was
substantially increased in A2780/SRSF3si2 cells treated
with Doxy but not in other Doxy-treated subline cells, in-
dicating that robust suppression of SRSF3, which resulted
in deeper downregulation of BRCA1, BRIP1 and RAD51
(Fig. 2), indeed caused accumulation of DSBs. Immuno-
fluorescent staining of A2780/SRSF3si2 cells treated with
or without Doxy confirmed above finding, as shown in
Fig. 5b. The time course of γ-H2AX levels after SRSF3
knockdown is shown in Additional file 3: Figure S6.
Next we examined whether knockdown of SRSF3 im-
paired cellular capability to repair DSBs via HR-mediated
pathway. We employed DR-GFP reporter [32] to analyze
HRR activity in the cell. The reporter consists of two tan-
dem mutated GFP genes with one being a full-length GFP
mutated to contain an I-SceI site and the other being a 5′
and 3′-truncated GFP in the downstream. A single DSB is
generated in the upstream GFP gene by ectopically
expressed I-Scel and can be repaired by HR with the
downstream truncated GFP as the template, which results
in the formation of functional GFP gene and thus GFP-
positive cells. Therefore, the percentage of GFP-positive
cells reflects the cellular capability to carry out HRR. We
performed this assay in 293 T cells because of the high
efficiency at which they can be transfected. As shown in
Fig. 5c, the percentage of GFP-positive cells is lowest in
293 T cells expressing SRSF3si2, indicating impaired HRR
in these cells. Although 293 T cells expressing SRSF3si1
also had lower percentage of GFP-positive cells than con-
trol cells, the difference between two was not statistically
significant. These results correspond well to the changes
of γ-H2AX shown in Fig. 5a and b.
Expression of siRNA-resistant SRSF3 offsets the effects of
knockdown of endogenous SRSF3
To further establish the role of SRSF3 in the regulation
of HRR gene expression, we conducted rescue study to
determine whether siRNA-resistant SRSF3 could offset
the effects of knockdown of endogenous SRSF3 in the
A2780/SRSF3si2 cells. We made three silent mutations
in the coding region of SRSF3 that was targeted by
SRSF3 siRNA2, as shown in Fig. 6a. The mutated entire
coding sequence with HA tag fused to the N-terminus
(HA-mutSRSF3) was then cloned into the lentiviral vector
pLVTHM [33] under the direction of EF-1α promoter, as
shown in Fig. 6b. pLVTHM was also the vector we used to
express the SRSF3 siRNAs and the luciferase siRNA in the
cell [16]. The expression of HA-mutSRSF3, like the ex-
pression of siRNAs, was Doxy-inducible in the cells ex-
pressing regulatory fusion protein tTR/KRAB, which is a
hybrid of the tetracycline repressor (tTR) and KRAB
A
B
Fig. 4 Knockdown of SRSF3 reduces RNApII occupancy on BRCA1, BRIP1 and RAD51 genes. a Regular PCR amplification of immunoprecipitated
chromatin DNAs. b qPCR analysis of immunoprecipitated chromatin DNAs. Shown are immunoprecipitated DNAs expressed as percentages of
corresponding input DNAs (mean ± s.d, n = 3). * and ** indicate p < 0.05 and p < 0.01, respectively, for comparisons of RNApII occupancy between
samples treated with and without Doxy
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domain of human Knox1 protein [33]. We infected A2780/
SRSF3si2 cells using the lentiviruses carrying HA-
mutSRSF3 expression cassette and obtained a new cell cul-
ture (A2780/SRSF3si2/mutSRSF3), which demonstrated
Doxy-induced expression of HA-mutSRSF3 and simultan-
eous suppression of endogenous SRSF3, as shown in Fig. 6c.
With these cells we observed that Doxy treatment caused
little changes in the expression of HRR-related genes
BRCA1, BRIP1 and RAD51, indicating that the expression
of HA-mutSRSF3 offset the effects of knockdown of en-
dogenous SRSF3 (Fig. 6c). In accordance with unchanged
expression of HRR-related genes, the expression of γ-
H2AX was not increased after Doxy treatment in these
cells (Fig. 6c), indicating that HA-mutSRSF3 rescued
DNA damages caused by knockdown of endogenous
SRSF3. Further, we found that HA-mutSRSF3 also pre-
vented SRSF3 knockdown-induced apoptosis, as shown
in Fig. 6d. Taken together, these rescue experiments
provide additional evidence to support a role of SRSF3
in the regulation of HRR and cell survival.
Knockdown of SRSF3 changes splicing pattern of lysine-
specific methyltransferase 2C (KMT2C, also known as MLL3)
and decreases methylated histone H3 lysine 4 (H3K4)
KMT2C is a H3K4-specific histone methyltransferase,
catalyzing H3K4 monomethylation [34, 35]. Our exon
microarray analysis found that KMT2C expression was
upregulated in SRSF3-knockdown cells (Additional file 1:
Table S1). According to Ensembl database, two large pro-
tein variants could be generated from this gene with one
being 4911 amino acids long and the other 4968 amino
acids long, depending on whether exon 45 is included. In
an attempt to validate the microarray finding, we ampli-
fied the region of KMT2C cDNA spanning exon 44 to
exon 46 from the samples of A2780 subline cells treated
with or without Doxy. As shown in Fig. 7a, the amplifica-
tion generated more DNA fragments than expected 2
DNA bands. More interestingly, SRSF3 knockdown chan-
ged the expression pattern of these fragments. Amplicon
sequencing of the PCR products from A2780/SRSF3si2
cells revealed that the extra fragments were derived from
A
B C
Fig. 5 Knockdown of SRSF3 increases accumulation of DSBs and impairs HRR activity. a Western blotting result of γ-H2AX. Cell lysates were
prepared from cell cultures treated with or without Doxy for 3 days. b Immunofluorescent staining of γ-H2AX in A2780/SRSF3si2 cells treated
with or without Doxy for 3 days. c Results of HRR assays. Shown are the percentage of GFP-positive cells determined by flow cytometry
(mean ± s.d., n = 4)
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the use of an alternative 3′ splice site (alt 3′ SS) within
exon 46, which is located 72 nucleotides downstream of 3′
SS of exon 46. Knockdown of SRSF3 increased the use of
the alt 3′ SS, resulting in substantial upregulation of splice
variants (represented by bands 2 and 4 in the image of
Fig. 7a) which had the 5′ portion of exon 46 (i.e. 46a in
the Fig. 7a) skipped and downregulation of splice variants
(represented by bands 1 and 3 in the image of Fig. 7a)
containing the whole exon 46. Given the molecular
function of KMT2C in H3K4 methylation, we won-
dered whether altered splicing of KMT2C was accom-
panied by any changes in H3K4 methylation. Therefore,
we examined monomethylated H3K4 (H3K4me1) and
trimethylated H3K4 (H3K4me3) in A2780/SRSF3si2
and the control A2780/LUCsi cells. As shown in Fig. 7b
and c, H3K4me1 and H3K4me3, especially the latter,
were decreased in Doxy-treated A2780/SRSF3si2 cells
but not in Doxy-treated control cells. In contrast, tri-
methylated H3K9 and H3K27 were basically unchanged
in Doxy-treated cells. H3K4me1 and H3K4me3 have
been associated with active transcription [34] while
H3K9me3 and H3K27me3 have been linked to gene re-
pression [36]. Whether the downregulation of BRCA1,
BRIP1 and RAD51after SRSF3 knockdown can be as-
cribed to the reduction of methylated H3K4 requires
more investigation to determine.
Discussion
In this report, we present data showing that knockdown
of SRSF3 results in downregulation of BRCA1, BRIP1
and RAD51 expression and causes impaired HRR activity.
These results suggest a novel role for SRSF3 in the
regulation of HRR pathway.
HRR is a major mechanism to repair DSBs, which are
the most deleterious form of DNA damage and can be
generated by exogenous insults as well as endogenous
factors [37]. In dividing cells like cancer cells, DSBs are
mainly caused by endogenous factors (endogenous
DSBs, EDSBs), such as reactive oxygen species (ROS)
and replication stress [37], and can be induced by acti-
vated oncogenes [38–41]. It was estimated that EDSBs




Fig. 6 Expression of siRNA-resistant SRSF3 offsets the effects of knockdown of endogenous SRSF3. a Mutated coding sequence of SRSF3 that is
targeted by SRSF3 siRNA2. Three silent mutations are in red. The sequencing chromatogram confirmed these mutations (indicated by the
underlined nucleotides). b A diagram of the lentiviral vector expressing Doxy-induced HA-mutSRSF3. c Western blotting results. d Percentage
of apoptotic cells
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Fig. 7 Knockdown of SRSF3 changes splicing pattern of KMT2C and decreases methylated H3K4. a RT-PCR of KMT2C transctipts between exon 44
and exon 46. The numbers in the middle of the image indicate the DNA bands. The diagram of the alternative splicing events is shown on the
right. The right and left arrows over exons 44 and 46 represent the primer pair used for PCR. b Detection of monomethylated H3K4 and trimethylated
H3K4, H3K9 and H3K27 by western blotting. Unmodified histone H3 was a loading control. c Quantitation of western blotting results in (b). The levels
of modified H3 were first normalized to the levels of unmodified H3 and then the relative levels of modified H3 were calculated using the samples
without Doxy treatment as the references
Fig. 8 Current model and the new one suggested by the results of this study to explain neoplastic transformation. TS: Tumor suppressor
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in the normal human cells [42]. In cancer cells, this rate
could be higher because of the effects of increased onco-
gene activity. DSBs are repaired primarily by two mecha-
nisms: non-homologous end-joining (NHEJ) and HRR
[43, 23]. NHEJ repairs DSBs by promoting direct ligation
of DNA ends, which frequently introduces insertions,
deletions, substitutions and even chromosome rear-
rangements. In contrast, HRR repairs DSBs faithfully by
using homologous sister chromatids as the template to
guide the repairing process and thus playing a pivotal
role in the maintenance of genomic stability [43, 23].
HRR involves following steps: DSB recognition, damage
signal transduction and break repair by HR [23]. The six
downregulated genes shown in Fig. 1c all have a role or
roles in this repair pathway [22, 23, 44]. For example,
BRCA1 helps to direct the cell to choose HRR over
NHEJ to repair DSBs during S and G2 phase [44].
BRCA1 is also required for the recruitment of RAD51to
the damage sites [45], which is necessary for homology
search and subsequent strand exchange with intact sister
chromatid duplex DNA [23].
If DSBs are left unrepaired or aberrantly repaired, the
outcome would be cell death or genomic instability. Al-
though genomic instability is a characteristic of most
cancers and is believed to facilitate the development of
permanent oncogenic changes in the genome [46], there
is no evidence suggesting that cancer cells could tolerate
continuous DNA damage generation after generation.
On the contrary, a relatively stable genome is essential
for any cell, normal or tumor, to grow and survive [47],
and it is cancer cell’s reliance on a stable genome that
makes DNA-damaging agents to be effective in cancer
treatment.
Given the more frequent occurrence of spontaneous
DSBs in cancer cells and the importance of a relatively
stable genome for cell growth and survival, it is logical
that cancer cells need upregulated HRR activity to keep
their genomes from continuous alterations. Otherwise,
accumulated DSBs or genomic alterations would eventu-
ally lead to cell death. The new role of SRSF3 in the
regulation of HRR pathway provides a mechanism for
cancer cells to meet this need. Therefore, it is no wonder
that almost all invasive ovarian tumors that we examined
overexpressed SRSF3 and knockdown of SRSF3 induced
growth inhibition and cell death [16]. Analysis of the
serous ovarian cancer microarray dataset from The Can-
cer Genome Atlas project shows that SRSF3, BRCA1,
RAD51, XRCC2 and BLM are upregulated in tumors
compared to normal ovaries, as shown in Additional file 3:
Figure S7, supporting the notion that tumor cells need
enhanced HRR activity.
The new role of SRSF3 discovered in this study also
suggests a new paradigm to understand the tumorigenic
process. It is widely accepted that activated oncogenes
are a driving force of tumorigenesis [48, 49]. However,
they alone cannot cause cancer. Instead, activated onco-
genes induce senescence or cell death in normal and par-
tially transformed cells due to their induction of DNA
damage and DNA damage response (DDR) [49, 40]. Ac-
cording to current tumorigenic model, after oncogene
activation, further genetic or epigenetic changes in
tumor suppressor genes are needed to overcome repli-
cative stress and make tumorigenesis proceed (Fig. 8,
left panel) [48, 49]. Our observation suggests that there
exist another mechanism to promote tumorigenesis.
That is, during neoplastic transformation, which could
be initiated by oncogene activation, SRSF3 is upregu-
lated by presently unknown factor(s) and confers cells
enhanced capability to carry out HRR and thus allows
cells to bypass replicative stress and complete trans-
formation process (Fig. 8, right panel). This new mech-
anism may explain not only the development of tumors
that lack mutations or alterations in tumor suppressors
involved in DNA damage repair and response but also
the overexpression of RAD51 found in a wide variety of
human tumors, including BRCA1-deficient ones [50, 51].
Overexpression of RAD51 can rescue the defects caused
by depletion of BRCA1 and thus may contribute to the
genesis of BRCA1-deficient tumors [51].
Finally, the results shown in Fig. 7 provide a clue to
understand the molecular mechanisms behind the new
role of SRSF3. Based on those results, we hypothesize
that SRSF3 regulates the expression of HRR-related
genes indirectly through an epigenetic pathway. That is,
SRSF3 controls alternative splicing of KMT2C, whose
splice variants determine the methylation status of
H3K4, by which the transcriptional activities of HRR-
related genes are set. To test the hypothesis, more work
will be needed to establish causal relationships between
the changed alternative splicing of KMT2C and reduced
methylated H3K4 and between reduced H3K4me3 and
suppressed expression of HRR-related genes.
Conclusions
Our results indicate that SRSF3 is a regulator of HRR
process, which possibly regulates the expression of HRR-
related genes indirectly through an epigenetic pathway.
This novel function explains why overexpression of
SRSF3 is required for ovarian cancer cell growth and
survival but also offers a new insight into the mechanism
of the neoplastic transformation.
Methods
Cell cultures
Ovarian cancer cell line A2780 sublines, A2780/SRSF3si1,
A2780/SRSF3si2 and A2780/LUCsi, were established in
our previous study [16]. These sublines were grown in
DMEM supplemented with 10 % FBS and 2 mM L-
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glutamine at 37 °C, 5 % CO2. 293 T cells were purchased
from the American Type Culture Collection (ATCC) and
grown in the same media as A2780 sublines.
Microarray analysis
Total RNAs were extracted from A2780/SRSF3si2 cells
grown in the presence or absence of Doxy (0.1μg/ml) for
3 days using TRIzol reagent (Life Technologies, Grand
Island, NY) and treated with TURBO DNA-free kit
(Life Technologies). The prepared total RNA samples
were submitted to Asuragen (Austin, TX) for expres-
sion profiling by Affymetrix Human Exon 1.0 ST Array
(Affymetrix, Santa Clara, CA). The microarray data
were analyzed using Partek Genomics Suite Version 6.6
(Partek, St. Louis, MO) to determine the differentially
expressed or spliced genes. Gene ontology analysis was
performed also using Partek Genomics Suite Version 6.6.
RT-PCR and qPCR
Total RNAs were extracted with TRIzol reagent from
cultured cells and treated with TURBO DNA-free kit.
cDNAs were synthesized from 2 μg of total RNAs with
High Capacity cDNA Reverse Transcription Kit (Life
Technologies). Non-quantitative RT-PCR reactions were
set up with Phusion Green Hot Start II High-Fidelity
DNA Polymerase (Thermo Fisher Scientific, Waltham,
MA). qPCRs were set up with Fast SYBR Green Master
Mix (Life Technologies) and run in StepOne Plus Real-
Time PCR System (Life Technologies). The primer pairs
for RT-PCR and qPCR were the same for each gene and
they are BRCA1 prime pair 5′-ACTCTGAGGACAAAG
CAGCG-3′ and 5′- CATCCCTGGTTCCTTGAGGG-3′,
BRIP1 primer pair 5′- CGCTTTAGGAATAACCCAAGT-3′
and 5′- CTCATTGTCCTGTATATTGGTT-3′, RAD51 pri-
mer pair 5′- TTTGGCCCACAACCCATT TC-3′ and 5′-
TTAGCTCCTTCTTTGGCGCA-3′, SRSF3 primer pair
5'-AATTGGAACGGGCTTTTGGC-3' and 5'-CCATCTAG
CTCTCGGACTGC-3', and GAPDH primer pair 5′-
GGGGCTGGCATTGCCCTCAA-3′ and 5′-GGCTGGTG
GTCCAGGGGTCT-3′. The expression level of each gene
was determined by the comparative CT (ΔΔCT) method
[52] with GAPDH as the endogenous control and the sub-
line A2780/LUCsi cells grown in the absence of Doxy as the
reference. The primer pair for amplification of KMT2C
cDNA between exon 44 and exon 46 was 5′-AGCACTGA
CACGTTTACCCA-3′ and 5′- AAGCCGGAGTGTTAG
TGAGC-3′.
Western blotting
Whole cell lysates were prepared with 1x sample buffer
(50 mM Tris pH 6.8, 2 % SDS, 10 % glycerol, 5 %
β-mecaptoethanol and 0.002 % bromphenol blue) and
sonicated with Sonifier Cell Disrupters (Branson Ultra-
sonics, Buffalo Grove, IL). Western blotting was performed
as described previously [53]. The antibodies for BRCA1,
RAD51, SRSF3 and γ-H2AX were purchased from Santa
Cruz Biotechnology (Dallas, TX, cat# sc-642, sc-8349, sc-
13510 and sc-101696, respectively) and the antibodies
for BRIP1 and UPF1 were from Cell Signaling Technol-
ogy (Danvers, MA; cat# 4578S, 12040S, respectively).
Quantitation of western blotting results was performed
with Volume Tools program contained in Image Lab
software (Bio-Rad Laboratories, Hercules, CA).
Apoptosis assay
Cells were fixed in 4 % paraformaldehyde for 10 min and
then stained in a solution of Hoechst 33342 (Life Tech-
nologies) for 15 min. Apoptotic cells and non-apoptotic
cells were counted under fluorescent microscope manually
with computer assistance.
ChIP
Chromatin DNAs were isolated from A2780/SRSF3si2
cells treated with or without Doxy for 3 days and immu-
noprecipitated with ChIP-IT Express Enzymatic kit (Ac-
tive Motif, Carlsbad, CA) and RNA polymerase II
antibody (mAb) (Active Motif, Cat # 39097) or Negative
control mouse IgG (Santa Cruz Biotechnology, cat# sc-
2762) by following the manufacturer’s instruction. The
primer pairs for non-quantitative PCR and qPCR were
the same for each gene and they are following: BRCA1
primer pair, 5′-GGACGTTGTCATTAGTTCTTTGGT-3′
and 5′-TCTTCAACGCGAAGAGCAGA-3′; BRIP1 primer
pair, 5′-GGGCTCCGCTTTATTTGCTC-3′ and 5′-CAGT
TGAGATCCCCGAGACC-3′; RAD51 primer pair, 5′-GC
TGGGGCGAAAACACAAG-3′ and 5′-GACTTCTCGCTC
GAACCCAT-3′; and GAPDH primer pair, 5′- TACTAGCG
GTTTTACGGGCG-3′ and 5′- AGGCTGCGGGCTCAAT
TTAT-3′. Non-quantitative PCRs and qPCRs were set up
as described in 2.2. The immunoprecipitated DNAs were
quantitated by standard curve method. The standard curve
was generated with input chromatin DNA samples at
concentrations of 50 ng, 5 ng, 0.5 ng and 0.05 ng per ul.
Immunofluorescent staining
A2780/SRSF3si2 cells were grown on poly-L-lysine-
coated glass coverslip in the presence or absence of
Doxy for 3 days before subjected for staining. The cells
were fixed in ice-cold methanol for 10 min followed by
air-dry. Afterwards, the cells were blocked in 5 % normal
donkey serum (Jackson ImmunoResearch, West Grove,
PA) for 1 h before they were incubated with γ-H2AX
antibody (Cell signaling Technology, Cat # 9718S, 1:400
dilution) for 1 h and then with Dylight 488-conjugated
donkey anti-rabbit IgG (Jackson ImmunoResearch, Cat #
711-485-152, 1:200 dilution) for 45 min. The cells were
rinsed in 1xPBS for three times after each incubation
step. Finally, the coverslips were mounted on glass slides
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with VECTASHIELD Mounting Medium containing
4′, 6-Diamidino-2-phenylindole dihydrochloride (DAPI)
(Vector Laboratories, Burlingame, CA).
HR assay
The direct repeat green fluorescent protein (DR-GFP) re-
porter was used to measure HR activity in 293 T cells with
or without SRSF3 knockdown. Briefly, 293 T cells grown in
12-well plate were infected at multiplicity of infection 5
with lentiviruses expressing SRSF3si1, SRSF3si2 or LUCsi
for 12 h. Two days after infection, these cells were co-
transfected with plasmids pDRGFP, pCBASceI (Addgene,
Cambridge, MA) and pmCherry-N1 (Clontech Labora-
tories, Mountain View, CA) by calcium phosphate
precipitation method [54]. The transfected cells were
subjected to flow cytometric analysis for GFP-positive and
mCherry-positive cells two days after transfection. The
percentages of GFP-positive cells were normalized to the
percentages of mCherry-positive cells before comparison.
Statistical analysis
Unless otherwise stated, Student’s t-test was used in
comparisons between samples. All tests were two-sided
and p-values < 0.05 were considered significant.
Accession numbers
The microarray data reported in this paper were depos-
ited in Gene Expression Omnibus (GEO) database. The
accession number is GSE71745.
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